Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
14.58
-0.12 (-0.82%)
Dec 5, 2025, 4:00 PM EST - Market closed
Phathom Pharmaceuticals Employees
Phathom Pharmaceuticals had 427 employees as of December 31, 2024. The number of employees decreased by 25 or -5.53% compared to the previous year.
Employees
427
Change (1Y)
-25
Growth (1Y)
-5.53%
Revenue / Employee
$344,707
Profits / Employee
-$642,974
Market Cap
1.02B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHAT News
- 14 days ago - Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth - Seeking Alpha
- 4 weeks ago - Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 4 weeks ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease - GlobeNewsWire
- 6 weeks ago - Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting - GlobeNewsWire
- 6 weeks ago - Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 - GlobeNewsWire